Skip to main content

Table 2 Association of clinical, pathological and genomic characteristics with PFS and OS in bevacizumab group

From: Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

Characteristics

N

(111)

Progression Free Survival

Overall Survival

   

HR

95% CI

P

HR

95% CI

p

Sex

Females

54

1

  

1

  
 

Males

57

0.86

0.52-1.41

0.535

1.17

0.57-2.40

0.669

Age

≤ 65 years

64

1

  

1

  
 

>65 years

47

1.19

0.72-1.99

0.487

1.25

0.60-2.70

0.528

ECOG PS

0

102

1

  

1

  
 

1-2

9

0.95

0.43-2.04

0.877

0.42

0.18-1.45

0.207

Primary tumor

Colon

82

1

  

1

  
 

Rectum

29

1.15

0.66-2.00

0.612

2.70

0.99-4.86

0.052

Mucinous histology

No

96

1

  

1

  
 

Yes

15

2.16

1.23-7.12

0.015

3.21

1.99-14.98

0.001

Previous adjuvant CT

No

66

1

  

1

  
 

Yes

45

1.84

1.17-3.37

0.011

1.25

0.60-2.69

0.531

Time to metastases

Metachronous

50

1

  

1

  
 

Synchronous

61

0.67

0.40-1.09

0.103

0.93

0.44-1.95

0.849

No. of metastatic sites

1

57

1

  

1

  
 

>1

54

1.22

0.75-2.02

0.421

1.77

0.85-3.62

0.130

Liver-only metastases

No

74

1

  

1

  
 

Yes

37

0.84

0.49-1.43

0.521

0.93

0.43-2.01

0.844

Resected primary tumor

No

15

1

  

1

  
 

Yes

96

2.11

0.99-3.40

0.052

1.09

0.34-3.48

0.887

High LDH level

No

69

1

  

1

  
 

Yes

31

0.86

0.48-1.50

0.574

1.41

0.64-3.26

0.376

 

Unknown

11

      

High CEA level

No

86

1

  

1

  
 

Yes

23

0.69

0.39-1.20

0.183

0.65

0.28-1.61

0.375

 

Unknown

2

      

Low HgB level

No

93

1

  

1

  
 

Yes

18

0.70

0.38-1.29

0.250

0.63

0.26-1.65

0.371

Leukocytosis

No

102

1

  

1

  
 

Yes

9

1.29

0.55-3.19

0.526

2.43

0.84-17.91

0.083

High ALP level

No

82

1

  

1

  
 

Yes

18

0.86

0.46-1.61

0.638

1.48

0.62-3.88

0.343

Low Albumin level

No

89

1

  

1

  
 

Yes

8

0.93

0.38-2.30

0.874

1.25

0.26-6.43

0.757

 

Unknown

14

      

Köhne score

Low

57

1

  

1

  
 

Intermediate-High

51

1.21

0.74-2.01

0.438

1.80

0.86-3.69

0.119

 

Unknown

3

      

-2578

A/A

16

1

  

1

  
 

A/C

60

1.02

0.50-2.07

0.959

1.19

0.41-3.38

0.753

 

C/C

35

1.53

0.74-3.26

0.246

1.36

0.42-4.65

0.581

-1498

C/C

22

1

  

1

  
 

C/T

60

1.82

0.98-3.55

0.056

2.49

0.98-6.16

0.056

 

T/T

29

2.65

1.49-6.62

0.003

2.47

0.91-7.76

0.074

+ 405

G/G

39

1

  

1

  
 

G/C

54

1.08

0.62-1.90

0.783

1.29

0.57-2.93

0.531

 

C/C

18

1.11

0.52-2.39

0.771

1.36

0.47-4.12

0.544

+ 936

T/T

2

1

  

1

  
 

C/T

31

1.38

0.35-5.38

0.642

1.60

0.27-8.47

0.645

 

C/C

78

1.04

0.25-4.35

0.955

1.39

0.23-7.96

0.741

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us